Last updated: September 5, 2026
Pevonedistat is an investigational NEDD8-activating enzyme inhibitor that has no FDA approval, no commercial launch, and no established product revenue. Takeda’s phase 3 PANTHER trial in higher-risk myelodysplastic syndromes (HR-MDS) failed to meet its primary endpoint, ending the drug’s principal development path. The base-case commercial projection is zero revenue through 2030 unless another company acquires the program and funds a new clinical strategy.
What is the current development status of pevonedistat?
Pevonedistat, also known as TAK-924 and MLN4924, inhibits the NEDD8-activating enzyme, or NAE. NAE inhibition disrupts cullin-RING ubiquitin ligases and can cause replication stress, DNA damage, and cancer-cell death.
Takeda evaluated pevonedistat primarily in hematologic malignancies, including:
- Higher-risk MDS
- Acute myeloid leukemia (AML)
- Relapsed or refractory AML
- MDS patients receiving azacitidine
- Selected solid-tumor studies in earlier development
The most important trial was PANTHER, a randomized phase 3 study comparing pevonedistat plus azacitidine with azacitidine alone in patients with higher-risk MDS. The study did not meet its primary endpoint. Takeda subsequently stopped pursuing regulatory submissions for the program in HR-MDS and removed the asset from its active commercial development strategy. [1, 2]
| Development item |
Status |
| Active ingredient |
Pevonedistat |
| Other names |
TAK-924; MLN4924 |
| Mechanism |
NEDD8-activating enzyme inhibitor |
| Lead sponsor |
Takeda Pharmaceutical Company |
| Main target indication |
Higher-risk MDS |
| Key trial |
Phase 3 PANTHER |
| PANTHER outcome |
Primary endpoint not met |
| FDA approval |
None |
| Commercial launch |
None |
| Current revenue |
None attributable to a marketed product |
| Development outlook |
Discontinued or inactive under Takeda’s program |
What did the phase 3 PANTHER trial show?
PANTHER evaluated whether adding pevonedistat to azacitidine could improve outcomes over azacitidine alone in higher-risk MDS. Earlier phase 2 data had suggested improvements in event-free survival and overall survival, creating a basis for the pivotal trial.
The phase 3 result did not confirm that benefit. Takeda reported that PANTHER failed to meet its primary endpoint. The company did not proceed with a US or European marketing application for pevonedistat in MDS. [1]
The failure has two commercial consequences:
- The most advanced indication lost its regulatory path.
- The remaining AML opportunity lacks a validated phase 3 efficacy package and would require substantial new investment.
The result also reduces the value of the earlier phase 2 findings. A positive signal in an exploratory or mid-stage study is insufficient to support commercialization after a negative pivotal study unless a company can identify a different population, combination regimen, biomarker, or endpoint.
What is the FDA regulatory status of pevonedistat?
Pevonedistat is not FDA-approved for MDS, AML, or any other condition. It has no approved prescribing information, no National Drug Code product, and no FDA-recognized commercial label.
The drug received FDA development designations during its clinical program, including Breakthrough Therapy Designation associated with the MDS program. Such designations can facilitate interaction with the FDA, but they do not guarantee approval or compensate for failure of a confirmatory trial. [3]
What is the Orange Book status of pevonedistat?
Pevonedistat has no Orange Book listing because it has no approved NDA. Consequently:
- There are no Orange Book-listed drug-substance patents.
- There are no Orange Book-listed drug-product patents.
- There are no listed method-of-use patents tied to an approved label.
- There is no reference-listed drug against which an abbreviated new drug application could currently be filed.
The absence of an Orange Book listing does not mean that every historical patent covering pevonedistat has expired. It means that no approved product currently creates an Orange Book-based patent certification or Paragraph IV litigation pathway.
How many patents cover pevonedistat?
A definitive count of active global patents cannot be inferred from FDA records because the drug has never received approval. Pevonedistat originated from Millennium Pharmaceuticals, later acquired by Takeda, and its historical intellectual-property portfolio likely includes compound, pharmaceutical-composition, therapeutic-use, and manufacturing claims.
The commercially relevant distinction is between:
- Core compound patents
- Salt, polymorph, or crystalline-form patents
- Combination-treatment patents
- MDS or AML method-of-use patents
- Formulation and injectable-product patents
- Manufacturing and intermediate patents
No public Orange Book record establishes an active, enforceable patent term for a marketed pevonedistat product. A patent-family review would need to separate granted claims from abandoned applications, expired priority families, terminal disclaimers, continuations, and jurisdiction-specific prosecution outcomes.
What formulations are protected by pevonedistat patents?
Pevonedistat was developed as an intravenous oncology drug. Public clinical records identify intravenous administration in combination with azacitidine and in other investigational regimens. [4]
The formulation risks are therefore different from those associated with oral small molecules. Potential protection could involve:
- Injectable solution or concentrate
- Stability during refrigerated storage
- Reconstitution or dilution procedures
- Intravenous dosing schedules
- Combination administration with azacitidine
No approved commercial formulation exists, and no FDA-approved product label establishes a final formulation patent position.
When does pevonedistat lose exclusivity?
Pevonedistat has no commercial exclusivity expiration date because it has never received FDA approval.
There is no standard US small-molecule exclusivity period currently running for the product:
| Exclusivity type |
Pevonedistat status |
| New chemical entity exclusivity |
Not awarded because no approval occurred |
| Orphan-drug exclusivity |
No approved indication |
| Pediatric exclusivity |
None identified |
| Qualified infectious-disease exclusivity |
Not applicable |
| Orange Book patent term |
No listed patents |
| Regulatory exclusivity expiration |
None |
Any historical patent expiration date would depend on the specific patent family and jurisdiction. That date would not create generic entry rights in the absence of an approved reference product.
Are there Paragraph IV challenges or patent litigation involving pevonedistat?
No established Paragraph IV challenge is associated with pevonedistat because the drug has no approved reference-listed product and no Orange Book patent listing.
The principal legal risk is therefore not generic litigation. It is the potential loss, expiration, abandonment, or non-enforcement of Takeda’s historical patent estate before a new sponsor can restart development.
No major public patent-litigation campaign has defined the pevonedistat program. There is also no known settlement agreement involving an ANDA challenger. Any future generic challenge would require a commercial relaunch, an approved NDA, and Orange Book-listed patents.
Which companies are challenging or developing alternatives to pevonedistat?
No company is publicly positioned as a direct commercial challenger to pevonedistat because the asset has not reached the market. Competitive pressure comes from therapies used in the same MDS and AML treatment settings.
In HR-MDS, azacitidine remains the principal benchmark regimen. Decitabine and oral decitabine/cedazuridine compete in selected settings. In AML, treatment options include intensive chemotherapy, venetoclax-based combinations, targeted agents for molecularly defined disease, and allogeneic stem-cell transplantation.
The relevant competitive issue is not whether another NAE inhibitor has displaced pevonedistat. It is whether a new sponsor could produce a differentiated clinical result against established hypomethylating-agent and venetoclax-based regimens.
How does pevonedistat compare with azacitidine and decitabine?
| Attribute |
Pevonedistat |
Azacitidine |
Decitabine |
| Regulatory status |
Investigational; no approval |
Approved for MDS and related indications |
Approved for MDS |
| Mechanism |
NAE inhibitor |
Hypomethylating agent |
Hypomethylating agent |
| Commercial status |
No launch |
Established product class |
Established product class |
| Main development issue |
Failed phase 3 confirmation |
Standard comparator |
Standard comparator |
| Administration |
Investigational intravenous regimen |
Injectable and oral formulations depending on product |
Injectable and oral decitabine/cedazuridine |
| Generic or branded competition |
No current generic pathway |
Generic and branded competition |
Generic and branded competition |
| Market access |
None |
Established reimbursement and clinical use |
Established reimbursement and clinical use |
Pevonedistat’s commercial proposition depended on improving outcomes when added to azacitidine. PANTHER did not establish that advantage. The drug therefore lacks a demonstrated basis for replacing existing hypomethylating-agent treatment.
What is the market projection for pevonedistat?
The base-case projection is zero commercial sales through 2030. The drug has no approval, no active regulatory submission, and no publicly established relaunch program.
Base-case scenario
Under the base case:
- Takeda does not restart the program.
- No third party acquires the asset for late-stage development.
- No new biomarker-defined indication is established.
- No new phase 3 trial is initiated.
- Revenue remains zero.
Upside scenario
An upside case would require a licensing transaction or asset acquisition followed by:
- A new clinical-development plan.
- Selection of a narrower responsive population.
- A credible combination strategy.
- New phase 2 evidence.
- A successful confirmatory trial.
- FDA approval and commercial launch.
Even under this scenario, launch would likely occur several years after program reactivation. A new sponsor would face the cost of reproducing clinical differentiation in a crowded hematology market.
Downside scenario
The downside case is permanent abandonment. This is commercially plausible because:
- The lead indication failed in phase 3.
- Competing regimens are established.
- No approved product generates cash flow to fund further trials.
- The asset requires additional clinical validation before regulatory filing.
- The original sponsor has already deprioritized the program.
What is the potential addressable market for a revived pevonedistat?
The theoretical market would include patients with higher-risk MDS and selected AML populations treated with hypomethylating agents. The practical market would be smaller because a revived product would need to demonstrate superiority or meaningful differentiation against:
- Azacitidine alone
- Decitabine-based therapy
- Azacitidine plus venetoclax in AML
- Mutation-directed AML therapies
- Transplant-based treatment
- Supportive care in patients unable to tolerate intensive regimens
A relaunch would likely require a biomarker strategy. Without patient selection, the negative phase 3 result would weaken physician adoption and payer coverage.
The highest-value commercial positioning would be a combination therapy that improves overall survival, transfusion independence, duration of response, or transplant eligibility without materially increasing infection, cytopenia, renal, hepatic, or gastrointestinal toxicity.
What manufacturing and intellectual-property barriers affect pevonedistat?
Pevonedistat is a complex oncology small molecule requiring controlled pharmaceutical manufacturing and intravenous drug-product development. Potential barriers include:
- Process reproducibility
- Control of impurities and intermediates
- Long-term stability
- Sterile manufacturing
- Compatibility with infusion materials
- Combination scheduling with azacitidine
- Protection of manufacturing know-how after patent expiry
These barriers could slow a generic or follow-on entrant, but they do not create a durable commercial moat without an approved product and enforceable claims.
How strong is the pevonedistat patent estate?
The patent estate has low demonstrated commercial strength because no approved product depends on it and no Orange Book listing supports enforcement against generic applicants.
Its residual value may lie in:
- Unexpired compound claims in selected jurisdictions
- Combination-use claims
- Manufacturing know-how
- Clinical data and regulatory history
- Potential repositioning in a biomarker-defined population
The negative phase 3 result materially reduces the value of use patents directed broadly to HR-MDS. Narrower claims covering a responder subgroup or a specific combination could retain value if new clinical evidence supports them.
Key Takeaways
- Pevonedistat is an investigational NAE inhibitor with no FDA approval or commercial revenue.
- The phase 3 PANTHER trial in higher-risk MDS failed to meet its primary endpoint.
- Takeda did not advance the drug to regulatory filing after the pivotal result.
- Pevonedistat has no Orange Book listing and no current Paragraph IV pathway.
- No FDA exclusivity expiration date applies because no approval occurred.
- The theoretical market includes HR-MDS and AML, but established therapies create substantial competitive pressure.
- The base-case revenue forecast through 2030 is zero.
- A commercial revival would require licensing, new clinical evidence, a differentiated population, and a successful confirmatory trial.
FAQs
Could pevonedistat still return to clinical development?
Yes, but a return would require a new sponsor or a strategic decision by Takeda, followed by a revised clinical hypothesis and additional trials. The failed PANTHER study makes a direct continuation in an unselected HR-MDS population unlikely.
Is pevonedistat a biosimilar risk?
No. Pevonedistat is a synthetic small molecule, not a biologic. Any future follow-on product would be evaluated through a generic or 505(b)(2)-type framework rather than the biosimilar pathway.
Does pevonedistat have orphan-drug exclusivity?
No active orphan-drug exclusivity applies because the product has not been approved for an orphan indication. A historical designation would not itself create market exclusivity.
Can a generic company launch pevonedistat now?
No commercial generic launch is available because there is no FDA-approved reference product. A future applicant would need to address FDA approval requirements, product quality, clinical bridging, and any surviving patent or regulatory rights.
What is the most likely strategic outcome for the asset?
The most likely outcome is continued inactivity or abandonment. An asset sale or licensing transaction is possible, but the economic case depends on finding a biologically defined subgroup or combination regimen that can overcome the negative phase 3 result.
References
- Takeda Pharmaceutical Company Limited. (2021). Takeda provides update on phase 3 PANTHER trial of pevonedistat in higher-risk myelodysplastic syndromes.
- ClinicalTrials.gov. (n.d.). A study of pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk myelodysplastic syndromes: NCT03297424. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (n.d.). Breakthrough therapy designation.
- ClinicalTrials.gov. (n.d.). Studies of pevonedistat in patients with hematologic malignancies. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.